Novo Nordisk Company Presentation

2 Novo Nordisk company presentation Novo Nordisk®
Anne Sofie Weekes Hald

and her daughter
Anne Sofie is living with
type 1 diabetes
2023 ‒ the 100th

anniversary year of
Novo Nordisk
As Novo Nordisk turns 100, we renew our commitment
to drive change for a healthy world.
While millions of people across the globe rely on our

life-saving medicines, we are also facing new challenges
in health.
Today, saving lives must go hand-in-hand with

improving health and well-being, with the ultimate
aspiration of a world free from the burden of disease.
Perseverance and collaboration have defined our past

and will define our future.
Together, we are driving change for generations.

4 Novo Nordisk company presentation
01 Our purpose
02 Driving change the Novo Nordisk Way
03 Driving change since 1923
04 Driving change through scientific &

digital innovation
05 Driving change in serious chronic

diseases
06 Driving change towards a sustainable

business Appendix:
Corporate strategy
07 Driving change with a long-term Strategic Aspirations
mindset for 2025
Our purpose
Driving change
to defeat serious
chronic diseases
Moustapha Djamil Cisse
Moustapha has type 1
diabetes and lives in Senegal
Since 1923 we have been innovating and

collaborating for better health – in medicine
and beyond.
The desire to create a future where fewer

people are burdened by serious chronic
diseases unites all of us in Novo Nordisk and
our partners.
Together, we are relentlessly driving change –

in our laboratories, in our health systems and
in our communities. For our children and for
our planet.
170 177
Supplier of nearly Total net sales Affiliates in
Novo 50%
of the world’s insulin billion DKK
80
countries
Nordisk Globally, we are

serving over About
at a glance 40
million patients
R&D centres
in China, Denmark,
India, UK and US
Strategic production
sites in Denmark, Brazil,
China, France and US
61,400
employees
Diabetes
Novo Nordisk is a leading global

healthcare company, founded in 1923
and headquartered in Denmark. Cardiovascular Rare diseases
disease
Our purpose is to drive change We do so by pioneering

to defeat serious chronic scientific breakthroughs,
diseases such as diabetes, expanding access to our
obesity and rare blood and
endocrine disorders.
medicines and working to
prevent and ultimately A top five
cure disease. pharma company measured
by market value1
1. https://companiesmarketcap.com/pharmaceuticals/largest-pharmaceutical-companies-by-market-cap/
(As of 5 January 2023). Obesity
Our global
presence
Corporate headquarters R&D centres
Bagsværd, Denmark China, Denmark, India, UK, US
North America Operations HQ Regional offices

Plainsboro, NJ, US • Beijing (China)
• São Paolo (Latin America)
International Operations HQ • Tokyo (Japan)
61,400 80
Zurich, Switzerland • Copenhagen (North West countries with
Europe) employees
worldwide affiliates
Strategic • Mainz (Germany)
production sites • Zurich (South East Europe,
Brazil, China, Denmark, France, Middle East & Africa
US • Dubai (Asia & Pacific)
ANNE SOFIE WEEKES HALD AND HER DAUGHTERS
Anne Sofie is living with type 1 diabetes
How we work
Driving change the

Novo Nordisk Way
Driven
by our
purpose
To drive change to defeat serious
chronic diseases, built upon our
heritage in diabetes.
Essentials
1 We create value by having a patient-

centred business approach. 6 We value diversity and treat everyone with
respect.
2 We set ambitious goals and are

empowered to achieve them. 7 We focus on performance and personal
development.
3 We are accountable for our financial,

environmental, and social performance. 8 We have a healthy and engaging working
environment.
4 We are curious and innovate for the

benefit of patients and society at large. 9 We strive for agility and simplicity in
everything we do.
5 We build and maintain good relations with

our stakeholders. 10 We never compromise on quality and
ethics.
Our heritage
Driving change
since 1923
August and Marie Krogh
brought back the rights to
manufacture insulin in Scandinavia
from the University of Toronto
Insulin: the beginning of our

journey to save and improve lives
Charles Best (left)
and Frederick
Banting at the
University of
Toronto
Our first patients
In March 1923, when Else was nine

years old and on the verge of dying,
The discovery of insulin
she became one of the first patients
Else Jeppesen to be treated with insulin produced
Before the discovery of insulin, (right) with a
by August Krogh and H.C. Hagedorn.
diabetes was a death sentence. friend
But in 1921, researchers in
This photo was taken two months
Toronto successfully extracted
later at which point Else’s condition
insulin from a dog’s pancreas and
had markedly improved. Else went
tested its effect, bringing hope
on the live a full life, raising two
for the first time to people with
daughters and a foster son.
diabetes.
August and
Marie Krogh
A love story for
As a doctor living with diabetes, In March 1923 the first
the ages
August and Marie Marie realised the importance patients received insulin
Krogh’s story of the discovery of insulin. She manufactured by Krogh and
reflects their love convinced her husband, Danish his partner Hans Christian
for one another
Nobel laureate August Krogh, Hagedorn.
and for humanity
to travel to Canada and seek
Today, the passion and
permission to produce this life-
determination of our
saving medicine in Denmark.
founders continues to inspire
us in everything we do.
It can
Brothers Thorvald (left)
and Harald Pedersen
founded Novo Terapeutisk
Laboratorium in 1925
be done!
Harald Pedersen, co-founder of
Novo Terapeutisk Laboratorium,
had a motto: “We can do better.”
Together with his brother Thorvald,

Harald worked tirelessly to refine
and optimise processes and to
innovate, an approach expressed
in a company saying: “It can be
done!”
Today, this relentless mindset

remains central to Novo Nordisk.
The Apis bull: A symbol of

our values
Part of our logo since 1925, the The Apis bull was worshipped
Apis bull reflects a tradition as the incarnation of Ptah,
among European chemists to creator of the universe, city
use animal symbols to god of Memphis and the
represent pharmacies. patron deity of craftsmen.
The logo is based on an ancient

Egyptian statuette that
symbolized the dualities of life
and death.
The evolution
of the company
1923 1925 1989 2000 2023

Nordisk Insulin- Novo Terapeutisk Merger of Novo Industri Demerger of Novo Nordisk into 100th anniversary
laboratorium Laboratorium and Nordisk Gentofte Novo Nordisk and Novozymes
Explore our 100 years

of driving change for
better health
Visit our interactive heritage experience to
explore how we have been driving change
for better health since 1923.
What we do
Driving change
through scientific &
digital innovation Marie Darting
Marie works in Oral Finished
Products in Denmark
Proteins & peptides
Our core expertise is discovering and developing therapeutic
proteins and peptides with world-leading capabilities in
protein expression, engineering and formulation.
Cell therapy
By using pluripotent stem cells we aim to develop
specialised cells for life-changing treatments that halt or
Our core
perhaps reverse progression of diseases which are caused
when particular cell types become lost or damaged.
RNAi
RNA interference (RNAi) therapies harness biological
technology
processes to selectively silence genes that cause or
contribute to disease.
RNA and gene therapies

Gene editing in the shape of inserting, deleting, modifying
platforms
or replacing DNA in the human genome holds the promise
of delivering a true cure for genetic diseases.
Delivery platforms
Injection devices & companion software

Our innovative devices and connected solutions combine
patient insight with engineering excellence to make drug
delivery as simple as possible.
Oral delivery
Most of our therapeutic peptides and proteins are injectable,
but we aim to make the latest innovations more accessible to
more patients through oral products.
Tomorrow’s innovative
cell therapies
Our cell therapy technology platform gives us a unique
opportunity to realise our purpose by working to develop life-
changing treatments for a range of serious chronic diseases:
Parkinson’s disease (PD)
Chronic heart failure (CHF)
Type 1 diabetes (T1D)

Increasing clinical trial

Increased participants
in Novo Nordisk clinical trials
activity around the world

60,000
To transform bold ideas into life-saving and preventive
>47,000
medicines, we are enrolling more people in our clinical trials patient
years in clinical
than ever before. trials
40,000
In 2022, more than We have

47,000 people took clinical trial 20,000
part in 151 clinical activity in

trials across 6,100 nine therapy
active investigator areas
sites in around 60 0
Patient years
countries of exposure 2019 2020 2021 2022

Enabling future
healthcare innovations Execute on the growing clinical pipeline
– timely and in the right quality
with data and

digitalisation Drive operational excellence through
automation and better data flow
We fully integrate all relevant data sources to enable Build and enable the right data
infrastructure
‘real-time’ analytics, fostering data-driven decisions that
maximise value for patients, society and our business.
Enable advanced analytics and data

insights to drive fact-based decision-
making and increase value of assets
Digital solutions
Real-world evidence
from Swedish pilot5
We employ digital technology to help people receive

the maximum therapeutic benefit from our medicines. Novo Nordisk smart
insulin pens led to…
Novo Nordisk
partners1
Glucose data from

BGM or CGM3 Dose guidance (Combined)
43%
fewer missed meal-time
insulin injections6
from digital data offer new
2
therapeutics (e.g. insights into
Dose data from regulated titration diabetes
smart pens4 apps) management
Tracks how much insulin

was taken and when
+2h
every day in good
glucose control7
1. Currently, Novo Nordisk smart pen integrations are in process and not fully in place for all partners’ solutions. Availability and timing will differ from partner to partner and country to country; 2. Dexcom is a registered trademark of Dexcom, Inc. in the United States and/or other countries. The connected smart solution for pre-filled insulin pens is currently the only
scope for integration with Dexcom products. The connected smart solution for durable insulin pens is currently available with the Dexcom products through the integration of diasend® by Glooko.; 3. Insulin dosing information is transferred from NovoPen® 6 and NovoPen Echo® Plus. Glucose information is transferred from blood or sensor-based glucose monitoring
systems. Both glucose and insulin dose data are designed to be viewed together on various existing in-clinic solutions; 4. NovoPen® 6 and NovoPen Echo® Plus are CE marked; a Novo Nordisk pre-filled add-on solution is also in development; 5. Patients in the Swedish pilot used their NovoPen® 6 to dose insulin, and the resulting data were viewed together with their
HCP using Glooko’s in-clinic solution; 6. Adolfsson A, Hartvig NP, Kaas A, et al. Improved insulin adherence after introduction of a smart connected insulin pen. Diabetes. 2019;68(Suppl.1):abstract 126-LB.; 7. Adolfsson P, Hartvig NP, Kaas A, et al. Increased time-in-range (TIR) observed after introduction of a connected insulin pen. Diabetes. 2019;68(Suppl.1):abstract
1067-P.; 8. Accu-Chek and Accu-Chek Guide are registered trademarks of Roche.© Roche Diabetes Care, 2020.
Pipeline overview
Source: Novo Nordisk Annual Report 2022.

Taking on urgent
global health challenges
Driving change
in serious chronic
diseases Abigail Conteh
Abigail has obesity and lives
in the United Kingdom
Non-communicable diseases (NCDs) are the

leading cause of death and disability globally 1
74%
of global deaths in 2019
were due to NCDs1
Four major NCDs drive the burden,

accounting for 33 million deaths 1
Diabetes Cardiovascular Cancer Chronic respiratory

diseases disease
Diabetes is a rapidly growing

social challenge worldwide
The increasing global

prevalence of diabetes1,2
46%
increase in number
of adults with diabetes
783 million
2045
adults with diabetes2
537 million
2021
285 million
2010
‘Rule of Halves’: only about 6% of people

with diabetes achieve desirable outcomes
Diabetes 100%
Get diagnosed
50%
Receive care
25% Achieve
treatment
targets Achieve desired
12.5% outcomes
~ 6%
Of the estimated about half are and of those, about and of those, about and only about 6% live a
537 million adults diagnosed*… half receive care*… half achieve treatment life free from diabetes-
with diabetes1… targets**… related complications.
* Actual rates of diagnosis, treatment, targets and outcomes vary in different countries; ** Recommended glucose levels
Type 2 diabetes is a
progressive serious chronic
disease characterised by raised
Type 2
blood sugar levels caused by
increasing insulin resistance
and failing pancreatic beta cell
function.
Treatment of people with type
diabetes
2 diabetes depends on the
stage of the disease. Initially,
oral medication is often
sufficient while progressed
stages require GLP-1 and
eventually insulin.
Pipeline highlights
• Once-weekly and glucose sensitive insulins, and
GLP-1 combinational therapy
• Several early projects aiming at improving
insulin sensitivity
• Several projects targeting the cardiometabolic
spectrum, a collection of conditions that includes
type 2 diabetes, cardiovascular disease, and 90%
chronic kidney disease Type 2 diabetes accounts for around
Cynthia Lindelwa Rilitiyana 90% of all cases of diabetes1
Cynthia has type 2 diabetes
and lives in South Africa
32 Novo Nordisk company presentation Roshni has type 1 diabetes Novo Nordisk®
and lives in India
Type 1 diabetes is a serious

chronic disease characterised by
an autoimmune destruction of
Type 1
the insulin-producing beta cells
in the pancreas leading to
absolute insulin deficiency.
People with type 1 diabetes are

dependent on daily insulin
diabetes
injections to control their blood
sugar levels and delay or reduce
diabetes complications.1
Pipeline highlights
• Prevention of type 1 diabetes
• Cure through disease modification &
beta cell replacement
Roshni
Roshni has type 1 diabetes
and lives in India
Team Novo Nordisk
Professional cycling team
Team Novo
Nordisk is
driving change
in diabetes
Team Novo Nordisk is a global all-diabetes
sports team spearheaded by the world’s
first all-diabetes professional cycling team.
The team’s mission is to inspire, educate

and empower people affected by diabetes,
and to promote an active and healthy
lifestyle.
41 athletes from +8.2 million followers 60+ events in 30

18 countries on social media1 countries in 2022
Obesity is a
global pandemic
813M adults live with
obesity2
175M
Obesity is linked to
multiple health
children and
complications,
adolescents live with
including heart obesity2
disease, type 2
diabetes and certain
types of cancers1
64% of people with

obesity are not
diagnosed3
Obesity is a progressive serious

chronic disease classified by a
BMI of 30 kg/m2 or greater and
influenced by many factors,
including physiological,
psychological, environmental,
socio-economic and genetic.
Obesity requires long-term
Obesity
management to delay or reduce
the risk of complications.
Pipeline highlights
• Diverse GLP-1-based solutions, including
oral and combination therapies
• Revolutionary amylin based treatments
• Projects on expanded mechanisms of
813M
energy expenditure, body composition,
and obesity-related complications
More than 813 million people live

Sarah Le Brocq with obesity1
Sarah has obesity and lives
in the United Kingdom
36 Driving change in serious chronic diseases Novo Nordisk®
Cardiovascular
Other serious
disease
Millions live with the risk of
chronic diseases
life-threatening complications
like heart attack or stroke
NASH
Novo Nordisk is entering new Pipeline highlights
therapy areas to address the • Semaglutide will spearhead
A silent disease poised to
high unmet medical needs our expansion into serious
become the leading cause of
within cardiovascular disease chronic diseases (NASH, AD
liver transplantation
(CVD), non-alcoholic and HFpEF*)
steatohepatitis (NASH) and • Strong cardiovascular
Alzheimer’s disease (AD). pipeline with assets
investigating new
These therapy areas bring new therapeutic approaches in
opportunities, while supporting atherosclerosis and heart
existing core capabilities, to failure
Alzheimer’s
serve more people in need of
new treatment options.
disease
A devastating
neurodegenerative disease
that impacts the whole family
*HFpEF: Heart Failure preserved Ejection Fraction

Cardiovascular disease (CVD)

covers conditions affecting the
heart or blood vessels. Multiple
treatments are available to
address these diseases, but
high unmet needs remain.
Cardiovascular Despite guideline

recommended standard of care
therapy, high-risk patients still
disease
experience high rates of
cardiovascular events, such as
heart attack and stroke.1
Pipeline highlights
We are investigating new therapeutic approaches
in atherosclerosis and heart failure, including a
novel anti-inflammatory approach with ziltivekimab
in two phase 3 trials (ASCVD and HFpEF), and an
anti-amyloid immunotherapy designed to deplete
amyloid deposits of the disease ATTR amyloidosis,
currently in phase 2. #1
CVD is the leading cause of
*HFpEF: Heart Failure preserved Ejection Fraction; ATTR: Transthyretin amyloidosis Angel Perea Zhucar
Angel has type 2 death worldwide2
diabetes and CVD
and lives in Mexico
NASH (non-alcoholic
steatohepatitis) is a serious,
progressive metabolic liver
disease characterised by
build-up of fat in the liver
(steatosis)1,2 It also involves
inflammation of the liver
tissue resulting in scaring of
NASH
the liver (fibrosis) that can
progress to cirrhosis.3
NASH is associated with

significant challenges4,5, many
of which can be linked to late
diagnosis and limited
treatment options.
Pipeline highlights
Following promising phase 2 results, semaglutide
is being further investigated in a phase 3 clinical
trial for the treatment of NASH. Furthermore, we
have a robust pipeline with an FGF-21 analogue
6.5%
and cagrisema, currently in phase 2, as well as
other molecules in early clinical development for
NASH.
NASH is present in up to 6.5% of
Liselotte Schjerning the general population6
Liselotte has NASH
and lives in Denmark
Alzheimer’s disease (AD) is the

most common cause of
dementia, a term describing a
Alzheimer’s
wide range range of symptoms
such as memory and
independence loss. AD slowly
impairs cognitive functions and
disease
the ability to do daily tasks. As
the disease progresses it leads
to personality and behavioural
changes, and is ultimately
fatal.8-12
Diagnosing AD is complex and

limited treatment options exist.
Pipeline highlights
Neuroinflammation is
Following promising pre-clinical, clinical and real- understood to play a key role in
disease progression.13
world evidence data, we are investigating
semaglutide in two phase 3 clinical trials for the
treatment of early Alzheimer’s disease (AD).
GLP-1 receptor agonists have been shown to
impact neuroinflammation1 and other pathways,2–7
which may provide neuroprotection in AD.
70-100M
People live with Alzheimer’s disease
worldwide14-17. And, global dementia
rates are set to triple by 2050.18
Rare diseases need Approximately
more than rare 7,000

solutions different rare
conditions exist2
Rare diseases, collectively, are

not so rare. Most are chronic, Heinz Vetterli Heinz
has haemophilia A
95%
lifelong and associated with
and lives in Around
350M
reduced quality of life and life
Switzerland
expectancy.
of rare diseases
The lack of awareness of rare people worldwide
diseases and lack of treatment
have no treatment
are affected2 options3
options can make the entire
experience, from diagnosis
onwards, one of challenges and
uncertainty.
72%
Average
diagnostic delay is
5 yrs of rare diseases

are genetic1
(up to 30 yrs)5,6
1 in 17
Partnering to shorten people will be affected by
the path to rare

a rare disease during
their lifetime1
disease diagnosis
An international public-private In addition to developing the core
consortium, Screen4Care aims early-diagnosis system,
to tackle a major hurdle for rare Screen4Care aims to establish a
14 countries and 35
disease patients – the lengthy digital ecosystem to empower partners are part of the
diagnosis journey. The patients, parents and caregivers as initiative1
innovative research approach is equal decision-makers in the
based on two central pillars: diagnosis process. This open
newborn genetic screening and innovation platform will hopefully
artificial intelligence (AI)-based lead to improved patient health and
tools. quality of life and an optimised use
of healthcare resources.
Liam Clemens
Liam has haemophilia A
and lives in the US
Haemophilia is an inherited
or acquired bleeding
disorder that prevents blood
from clotting.
Without treatment,
uncontrolled internal
bleeding can cause stiffness,
Haemophilia
pain, severe joint damage
and even death. Some
people with haemophilia
develop inhibitors against
traditional treatments.
– a rare blood disorder
Pipeline highlights
Subcutaneous treatments of
haemophilia with and without 1 in
10,000
inhibitors
people are born with

Sierra Clark haemophilia1
Sierra has Glanzmann Thrombasthenia
Manuel Melendez
and lives in CanadaManuel has haemophilia A
and lives in Mexico
Sickle cell disease (SCD) is a

group of rare genetic blood
disorders. The most common
type is known as sickle cell
Sickle cell
anaemia (SCA). It results in an
abnormality in haemoglobin, the
oxygen-carrying protein in red
blood cells.2
A number of health problems
disease
may develop, such as attacks of
pain (known as a sickle cell crisis
or vaso occlusive crisis),
anaemia, infections, lung
problems and stroke. Long-term
pain may develop as people get
– the most common rare congenital older.3 The average life

expectancy in the developed
blood disorder1 world is 40 to 60 years.4
Pipeline highlights
Oral and subcutaneous disease ~17
million
modifying treatments for sickle cell
disease patients
people live with sickle cell

Jenica Leah disease5
Jenica has sickle cell anaemia and
lives in the United Kingdom
Growth
Growth related disorders affect
a person’s height, weight,
development and healthy
function of the human body.
Although the causes range
related
from poor nutrition to more
serious underlying medical
conditions, these disorders
may present reduced levels of
disorders
growth hormone.
– a group of a rare endocrine disorders
1 out of…
Pipeline highlights
• Once-weekly treatment may support
adherence and persistence 1 child out of ~ 4,000 is born with
• A platform for connected devices to growth hormone deficiency1
help manage patients’ therapy 1 girl out of ~ 2,500 is born with

Turner Syndrome2
1 child out of ~ 1,000-2,500 is born

Holly Lloyd-Garwood with Noonan Syndrome3
Holly has growth hormone
deficiency and lives in the
United Kingdom
Hormone
Menopause is characterised by
hormonal changes, resulting
from loss of ovarian follicular
activity. This can lead to both
psychological and physical
replacement
discomfort for many women.
Novo Nordisk is one of the
world’s largest manufacturers
of HRT products.
therapy
We offer a range of low dose medicines
for the effective treatment of
menopausal symptoms tailored to the
individual needs of women.
Lotte Malling
Lotte has received HRT
treatment and lives in Denmark
Product overview
Source: Novo Nordisk Annual Report 2022.

47 Novo Nordisk®
Our ambition is to be a sustainable

business that adds value to society
Driving change
towards a sustainable
business
Sustainable
business
By being a sustainable Driving change
business we add value to to defeat serious
society and to our future chronic diseases
business.
Within social and

#1 Reach more
#3 Reduce CO2
environmental patients emissions
responsibility we
are focusing on
four must-win
challenges
#2 Develop new business

models for preventing obesity #4 Reduce the plastic footprint
from our products
Driving change Together, we are driving change to defeat serious chronic
as a sustainable diseases through…
business
Novo Nordisk aims to run a
sustainable business – one that
is socially, environmentally and
financially responsible.
Our social responsibility strategy,

which consolidates many of our
existing initiatives and sets out new
ambitions for the future, is
structured around three key areas: Prevention Access & Innovation
Prevention, Access and Affordability, affordability
and Innovation.
Bend the obesity and diabetes Provide access to affordable care Explore transformative
curve and reduce overweight and for vulnerable patients worldwide; treatments and strive for curative
obesity in children; focus on improve supply chains and therapies for serious chronic
health inequality in cities strengthen treatment capacity diseases
Driving change We are embracing a circular mindset – our ambition is
as a sustainable zero environmental impact
business
Novo Nordisk aims to run a
sustainable business – one that
is socially, environmentally and
financially responsible.
Novo Nordisk’s environmental

ambition is to have zero
environmental impact. To get there we
are embracing a circular mindset –
designing and producing our products Circular supply Circular company Circular products
so that they can be recovered and re-
used, and reshaping our business
practices to minimise consumption Engage with suppliers Reduce the environmental impact Minimise the environmental
and eliminate waste by turning it into to minimise the environmental from our own operations impact from our products, also
new resources. impact from what we buy after use
Driving change to take on the

rise of serious chronic diseases
Prevention
Driving change to
prevent childhood
obesity
From 2000−2016, the proportion of
children affected by overweight
(5−19 years old) rose from 1 in 10 to
almost 1 in 53 Novo Nordisk and UNICEF are combining
their expertise, reach and convening power
to contribute to preventing childhood
overweight and obesity.
The number of children affected by
overweight has increased in all The partnership is focusing on three main
continents, including in Africa2
approaches: addressing gaps in knowledge
and sharing best practice; supporting
38M
decision-makers to act; and helping to scale
up interventions that work.
children under 5 worldwide are
affected by overweight and the toll
from overweight and obesity keeps
rising1
©UNICEF México/Balam-Ha Carrillo

Cities
changing
diabetes
The Cities Changing Diabetes programme
works to map the problem of obesity and
40+
type 2 diabetes in cities, share learnings and
act as a catalyst for meaningful action that
More than 40 partner cities can help bend the urban diabetes curve.
In partnership we are calling on every city to
220M+ ask itself:
“What will it take to bend the diabetes curve

Representing more than
220 million citizens1 in our city?”
Mexico City
Driving change for the most

vulnerable patients in every country
Access to
care
Bilguissa Balde
Bilguissa has type 1 diabetes
and lives in Guinea
The WDF was founded by

Novo Nordisk in 2002 as
an independent and non-
profit foundation.
1,492M DKK granted1
584K
Its vision is to alleviate human
suffering related to diabetes
among those in greatest need.
HCPs trained1
Today, the WDF is a leading
global funder of diabetes
prevention and care projects in
low- and middle-income
countries.
595 projects funded1

The Novo Nordisk

Haemophilia Foundation
(NNHF) was founded by
Novo Nordisk in 2005,
28.31M CHF granted1
as an independent non-
580
profit organisation.
It is dedicated to improving
access to care for people with Haemophilia centres
haemophilia and allied disorders established or
in low- and middle-income strengthened1
countries.
The NNHF funds programmes to

build capacity for diagnosis and
care, encouraging its partners to
326
join forces for sustainable impact
and systemic change.
The foundation strives to Programmes

empower people with
funded1
haemophilia and allied disorders
to raise awareness, advocate with
a united voice and live full lives.
Changing
Ma Yin May Oo and her mother
Ma Yin has type 1 diabetes
and lives in Myanmar
Diabetes® in
Children
41,033 This public-private partnership provides
access to comprehensive diabetes care,
children and youth
including insulin and supplies free-of-charge,
reached1
to children with type 1 diabetes.
More than
In 2022, the partnership operated in 26 low-
335 and middle-income countries*, in
collaboration with global and local partners.
clinics established or
refurbished1
Our goal is to reach 100,000 children and
youth by 2030.
23,185
Healthcare workers
trained1
Access to Insulin
Commitment
(A2IC)
➢ The Commitment is to provide low-
priced human insulin at a ceiling price
in the poorest parts of the world for
many years to come.
➢ In 2022, the Commitment scope included

76 low- and middle-income countries
and select international organisations
1.8M
providing humanitarian relief.
➢ The ceiling price is set at 3 USD since

1.8 million patients with 2020.
diabetes received human
insulin vials under 3 USD
through this commitment in Khady Wade
20221 Khady has type 1 diabetes
and lives in Senegal
EAST ALEPPO, SYRIA

Syrian Arab Red Crescent (SARC) were
granted access to Masaken Hanano, one
Humanitarian
Programme
of the districts in East Aleppo,
in order to assess the living conditions.
© ICRC
The Humanitarian Programme provides support for people

with diabetes who are affected by humanitarian crises.
The programme has three components:

• Supplying insulin to humanitarian organisations
• Building capacity in humanitarian settings
• Support advocacy efforts
Two partnerships are part of this programme:
Partnering for Change: In partnership with the

Red Cross, working towards improving access
to chronic care in humanitarian crises
263,000 Senselet: Strengthening healthcare supply

chain management in Ethiopia together with
patients reached1 WDF, Kuehne Foundation and others
263,000 patients were reached

through humanitarian sales
and donations in 2022
Driving change towards zero environmental

impact – for society and our planet
Eliminate environmental impact
Novo Nordisk Favrholm Campus,

Hillerød, Denmark
Working across the value chain

to achieve zero impact
CIRCULAR SUPPLY CIRCULAR COMPANY CIRCULAR PRODUCTS

Engage with suppliers Reduce environmental impact Minimise the environmental
to minimise the environmental from own operation impact from our products,
impact from what we buy also after use
Net Zero by 2045, scope 1, 2 and 3
Scope 1 Scope 2 Scope 3

Company owned or Purchased energy All emissions outside own
controlled resources operations—from goods
purchased to disposal of
products
Circular for Zero targets
Zero CO2 Zero

Net Zero All supply
from own production
based on 100%
emissions operations waste
renewable
by 2045 and transport to landfill
power by 2030
by 2030 by 2030
All Novo Nordisk production is

sourcing renewable power worldwide
Denmark
Wind power
New Hampshire Russia China
Solar power Wind power Wind power
France
Wind power
Japan
North Carolina Iran Biomass and solar
Solar power Algeria Wind power power
Wind power
Brazil
Hydropower
Our approach on how to reduce plastic
Reduce Change to non-virgin- Avoid plastic

our use of plastic fossil plastic on landfill
We are
recycling waste “It has been
absolutely fantastic
to work with Novo Nordisk.
I never imagined that such
a small company like ours
could work with such a large
In collaboration with Danish design firm company. It may also be
an inspiration to others"
Hay, we are turning used plastic into office
Pernille Bülow,
chairs. Glass blower
Designer Pernille Bülow is recycling Novo

Nordisk glass into lamps, vases, bowls and
more.
Students from Technical University +90% of the
of Denmark (DTU) participated in plastic waste
innovation challenge. Winning concept was from our pen
Shopping Basket, entirely made of recycled production is
injections pens. now recycled
DK TakeBack
pilot: returpen™
Danish pilot scaled
to a national solution by Feb 2022
Partnership: 15 public and

private organisations
Return rate of 20% after first pilot year
Return rates trending very positively

after scaling to national solution
Global TakeBack Programme:

Solve end-of-life product challenge
DK TakeBack
Progress to date: pilot:
generate
National Scale: The Danish pilot was scaled learnings
nationwide in February 2022, and the British 2020
Pilots in UK,
pilot in September 2022 Brazil, France:
create a Novo
Pilot period: Started in Brazil in 2021 and Nordisk
France in 2022 solution
2021+
In progress: Italy, Germany and Japan are in
the preparation phase
Back end solution in progress Build an
industry
Many affiliates interested (+9) solution:
Collaborate with
peers to build
solution beyond
Novo Nordisk
2030
External commitments, ratings and partnerships
Commitments Ratings Partnerships
Climate
Our foundation and

management
Driving change
with a long-term
mindset
Annika_Bertling and
Vibeke_Hatorp work in
Regulatory Affairs in Denmark
Novo Nordisk The Novo Nordisk Foundation is an independent
Foundation foundation with corporate interests. Through its

wholly-owned subsidiary, Novo Holdings A/S, the
Foundation is the main shareholder in Novo
Nordisk A/S and Novozymes A/S.
Dividends
The Foundation’s purpose is to provide a stable

100% shares
basis for the commercial and research activities
of the Novo Group1 companies, and to support
scientific as well as humanitarian and social
projects.
Vision
Grants are given within three focus areas: Health,
sustainability, and the life science ecosystem, which include
Dividends
biomedical and health science research, natural and
technical science research, life science, biotech and
biosustainability research, diabetes patient care, innovation,
education and social and humanitarian projects.
To improve people’s health and
the sustainability of society and > 25% shares 2 > 25% shares 2
the planet.
1. The Novo Group comprises Novo Holdings A/S, 2. A-shares have 10 times voting power per share.
Novo Nordisk A/S and Novozymes A/S
Executive
Management
Lars Fruergaard Jørgensen
President and chief executive officer (CEO)
International Rare Disease Finance, Legal & North America Development Corporate People & Research & Commercial Strategy Product Supply,
Operations Global Solutions Operations Development Organisation Early Development & Corporate Affairs Quality & IT
Maziar Mike Doustdar Ludovic Helfgott Karsten Munk Knudsen Doug Langa Martin Holst Lange Dave Moore Tania Sabroe Marcus Schindler Camilla Sylvest Henrik Wulff
Executive vice president Executive vice president Executive vice president, Executive vice president Executive vice president Executive vice president Executive vice president Executive vice president, Executive vice president Executive vice president
and head of International and head of Rare Disease chief financial officer and head of North and head of Development and head of Corporate and head of People and chief scientific officer and head of Commercial and head of Product
Operations (CFO) and head of America Operations Development Organisation (CSO) and head of Strategy and Corporate Supply, Quality and IT
Finance, Legal and Global Research and Early Affairs
Solutions Development
Board
of Directors
Helge Lund Henrik Poulsen Laurence Debroux Andreas Fibig Sylvie Grégoire Elisabeth Dahl Christensen
Chair of the Board Vice chair of the Board Member of the Board Member of the Board Member of the Board Member of the Board
Chair of the Nomination Member of the Audit Committee Chair of the Audit Committee Member of the Research & Member of the Audit (employee representative)
Committee Member of the Remuneration Member of the Remuneration Development Committee Committee, the Research & Member of the Remuneration
Committee Committee Development Committee and Committee
the Nomination Committee
Jeppe Christiansen Mette Bøjer Jensen Kasim Kutay Liselotte Hyveled Martin Mackay Thomas Rantzau Christina Law
Member of the Board Member of the Board Member of the Board Member of the Board Member of the Board Member of the Board Member of the Board
Chair of the Remuneration (employee representative) Member of the Nomination (employee representative) Chair of the Research & (employee representative) Member of the Audit
Committee Member of the Audit Committee Member of the Research & Development Committee Member of the Nomination Committee
Committee Member of the Research & Development Committee Member of the Remuneration Committee
Development Committee Committee
Sandipa Dey, Natalia Datta

& Neetima Bhardwaj
Global Service Centre
India
More about
Novo Nordisk
Novonordisk.com linkedin.com/company/novo-nordisk
facebook.com/novonordisk youtube.com/novonordisk
twitter.com/novonordisk instagram/novonordisk
TikTok/novonordisk
Team Novo Nordisk ambassador

Fiona Wylde
Appendix
77 Corporate Strategy Novo Nordisk company presentation Novo Nordisk®
Our purpose and the NNWay are at the core of our strategy
Diabetes Obesity
Strengthen leadership by Strengthen leadership through
offering innovative medicines market development and by
and driving patient offering innovative medicines
outcomes and driving patient outcomes
Rare Disease Other Serious

Secure a leading position Chronic Diseases
by leveraging full portfolio Establish presence by
and expanding into building competitive pipeline
adjacent areas and scientific leadership
Strategic Aspirations for 2025
• Further raise the innovation-bar for diabetes treatment
therapeutic focus
• Progress towards zero environmental impact • Develop a leading portfolio of superior treatment
Innovation and
solutions for obesity
• Being respected for adding value to society
sustainability
Purpose and
• Strengthen and progress the Rare disease pipeline

• Being recognised as a sustainable employer
• Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
(ESG)
• Deliver solid sales and operating profit growth

• Deliver 6-10% sales growth in IO
• Strengthen Diabetes leadership - aim at global value
market share of more than 1/3 • Transform 70% of sales in the US1
• More than 25 billion DKK in Obesity sales by 2025 • Drive operational efficiencies across the value chain to
Commercial
enable investments in future growth assets

execution
Financials
• Secure a sustained growth outlook for Rare disease
• Deliver free cash flow to enable attractive capital
allocation to shareholders
1From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.

Novo Nordisk Company Presentation

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Novo Nordisk Company Presentation

Uploaded by

Copyright:

Available Formats

2 Novo Nordisk company presentation Novo Nordisk®

Anne Sofie Weekes Hald

2023 ‒ the 100th

While millions of people across the globe rely on our

Today, saving lives must go hand-in-hand with

Perseverance and collaboration have defined our past

Together, we are driving change for generations.

02 Driving change the Novo Nordisk Way

03 Driving change since 1923

04 Driving change through scientific &

05 Driving change in serious chronic

06 Driving change towards a sustainable

Since 1923 we have been innovating and

The desire to create a future where fewer

Together, we are relentlessly driving change –

Nordisk Globally, we are

Novo Nordisk is a leading global

Our purpose is to drive change We do so by pioneering

North America Operations HQ Regional offices

Driving change the

1 We create value by having a patient-

2 We set ambitious goals and are

3 We are accountable for our financial,

4 We are curious and innovate for the

5 We build and maintain good relations with

Insulin: the beginning of our

Our first patients

In March 1923, when Else was nine

Together with his brother Thorvald,

Today, this relentless mindset

The Apis bull: A symbol of

The logo is based on an ancient

1923 1925 1989 2000 2023

Explore our 100 years

RNA and gene therapies

Injection devices & companion software

Parkinson’s disease (PD)

Chronic heart failure (CHF)

Type 1 diabetes (T1D)

Increasing clinical trial

activity around the world

In 2022, more than We have

part in 151 clinical activity in

countries of exposure 2019 2020 2021 2022

with data and

Enable advanced analytics and data

We employ digital technology to help people receive

Glucose data from

Tracks how much insulin

Source: Novo Nordisk Annual Report 2022.

Non-communicable diseases (NCDs) are the

Four major NCDs drive the burden,

Diabetes Cardiovascular Cancer Chronic respiratory

Diabetes is a rapidly growing

The increasing global

‘Rule of Halves’: only about 6% of people

Treatment of people with type

and lives in India

Type 1 diabetes is a serious

People with type 1 diabetes are

The team’s mission is to inspire, educate

41 athletes from +8.2 million followers 60+ events in 30

64% of people with

Obesity is a progressive serious